First Response: NSCLC Highlights From Chicago

18

TAGS:

description

First Response: NSCLC Highlights From Chicago. RTOG 0617 Overall Survival Results. ALK Rearrangement Positive Advanced NSCLC. MPDL3280A Phase Ia: Response by PD-L1 IHC Status. GALAXY-1 Overall Survival: Adenocarcinoma. LUME Lung 1: Overall Survival Adenocarcinoma. - PowerPoint PPT Presentation

Transcript of First Response: NSCLC Highlights From Chicago

Page 1: First Response: NSCLC Highlights From Chicago
Page 2: First Response: NSCLC Highlights From Chicago
Page 3: First Response: NSCLC Highlights From Chicago
Page 4: First Response: NSCLC Highlights From Chicago
Page 5: First Response: NSCLC Highlights From Chicago
Page 6: First Response: NSCLC Highlights From Chicago
Page 7: First Response: NSCLC Highlights From Chicago
Page 8: First Response: NSCLC Highlights From Chicago
Page 9: First Response: NSCLC Highlights From Chicago
Page 10: First Response: NSCLC Highlights From Chicago
Page 11: First Response: NSCLC Highlights From Chicago
Page 12: First Response: NSCLC Highlights From Chicago
Page 13: First Response: NSCLC Highlights From Chicago
Page 14: First Response: NSCLC Highlights From Chicago
Page 15: First Response: NSCLC Highlights From Chicago
Page 16: First Response: NSCLC Highlights From Chicago
Page 17: First Response: NSCLC Highlights From Chicago
Page 18: First Response: NSCLC Highlights From Chicago

Biomarker testing in non- small cell lung cancer (NSCLC) · NSCLC is both histologically and genetically diverse. 3. Prevalence of genetic alterations in NSCLC. 4. 40%. 25%. 10%.

Biomarker testing in non- small cell lung cancer (NSCLC) · NSCLC is both histologically and genetically diverse. 3. Prevalence of genetic alterations in NSCLC. 4. 40%. 25%. 10%.

Surgical Approach to NSCLC

Surgical Approach to NSCLC

Tratamiento TKI-estudio IFUM NSCLC

Tratamiento TKI-estudio IFUM NSCLC

HIGHLIGHTS OF PRESCRIBING INFORMATION When … · Non-Small Cell Lung Cancer (NSCLC) •in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment

HIGHLIGHTS OF PRESCRIBING INFORMATION When … · Non-Small Cell Lung Cancer (NSCLC) •in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment

Treatment of ALK Positive Advanced NSCLC · Treatment of ALK Positive Advanced NSCLC ... • First identified in NSCLC cells in 2007 ... Chemistry of ALK Tyrosine Kinase Inhibitors

Treatment of ALK Positive Advanced NSCLC · Treatment of ALK Positive Advanced NSCLC ... • First identified in NSCLC cells in 2007 ... Chemistry of ALK Tyrosine Kinase Inhibitors

Improving Outcomes in Advanced NSCLC with Immune ...•5-year survival rate is 19% (NSCLC + SCLC) •From 2009–2015, the relative survival rate for NSCLC was 25% •Recent overall

Improving Outcomes in Advanced NSCLC with Immune ...•5-year survival rate is 19% (NSCLC + SCLC) •From 2009–2015, the relative survival rate for NSCLC was 25% •Recent overall

NSCLC: Targeted Therapies and Beyond · approved for the treatment of NSCLC. There are also drugs that target specific NSCLC–associated mutations. For example, 10-35 percent of

NSCLC: Targeted Therapies and Beyond · approved for the treatment of NSCLC. There are also drugs that target specific NSCLC–associated mutations. For example, 10-35 percent of

Chemo rt in nsclc 2011- jk

Chemo rt in nsclc 2011- jk

Bristol-Myers Squibb -- ASCO 2015 Highlights · ASCO 2015 NOT FOR PRODUCT PROMOTIONAL USE 23 Checkmate-057: Phase 3 Non-Squamous NSCLC . Non-Squamous Cell NSCLC . Nivolumab 3 Q2W

Bristol-Myers Squibb -- ASCO 2015 Highlights · ASCO 2015 NOT FOR PRODUCT PROMOTIONAL USE 23 Checkmate-057: Phase 3 Non-Squamous NSCLC . Non-Squamous Cell NSCLC . Nivolumab 3 Q2W

nonsquamous NSCLC

nonsquamous NSCLC

THE UNIVERSITY OF CHICAGO PRESS Highlights for Fall 2019

THE UNIVERSITY OF CHICAGO PRESS Highlights for Fall 2019

HIGHLIGHTS OF PRESCRIBING INFORMATION …...• Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based

HIGHLIGHTS OF PRESCRIBING INFORMATION …...• Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based

Medical School of Oncology Highlights on NSCLC Management STAGING STRATEGIES Maria Grazia Ghi Divisione di Oncologia-Venezia Roma, 29 ottobre 2010.

Medical School of Oncology Highlights on NSCLC Management STAGING STRATEGIES Maria Grazia Ghi Divisione di Oncologia-Venezia Roma, 29 ottobre 2010.

From Inquiry to Investigation to Insight: Clinical Clarity in … · 2019. 12. 6. · EGFR in NSCLC •10% of NSCLC cases in North America •30%–50% of NSCLC cases in East Asia

From Inquiry to Investigation to Insight: Clinical Clarity in … · 2019. 12. 6. · EGFR in NSCLC •10% of NSCLC cases in North America •30%–50% of NSCLC cases in East Asia

Maintenance therapy for NSCLC

Maintenance therapy for NSCLC

PANERA BREAD (Corporate|Chicago MSA) 5500 West Touhy ... Bread - Skokie, IL - OM.pdfINVESTMENT HIGHLIGHTS: INVESTMENT HIGHLIGHTS • Located within the Chicago MSA • New construction

PANERA BREAD (Corporate|Chicago MSA) 5500 West Touhy ... Bread - Skokie, IL - OM.pdfINVESTMENT HIGHLIGHTS: INVESTMENT HIGHLIGHTS • Located within the Chicago MSA • New construction

Predicting NSCLC prognosis by automated pathology

Predicting NSCLC prognosis by automated pathology

CHICAGO CHAPTER ICRI · 2017. 2. 20. · ICRI Chicago Chapter November Dinner 10 Meeting Announcement ICRI Chicago Chapter April Dinner 11 Meeting Highlights 5th Annual Chicago Chapter

CHICAGO CHAPTER ICRI · 2017. 2. 20. · ICRI Chicago Chapter November Dinner 10 Meeting Announcement ICRI Chicago Chapter April Dinner 11 Meeting Highlights 5th Annual Chicago Chapter

The Evolving Treatment Landscape in NSCLC

The Evolving Treatment Landscape in NSCLC

Mlm nsclc prevencion_oportuno_2016_b

Mlm nsclc prevencion_oportuno_2016_b